The NIH-funded trial was conceived when a genomics researcher asked to present to the board and explained that while people of African ancestry have increased risk of kidney failure due to numerous socioeconomic, environmental, and clinical factors, variants in the APOL1 gene account for much of the racial disparity associated with hypertensive kidney failure [11]. The gene discussed is APOL1; the disease is kidney failure.